Agios Pharmaceuticals | AGIO - Cash And Equivalent


Agios Pharmaceuticals reported $92.71M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.63B 838M Sep/2025
Agios Pharmaceuticals USD 92.71M 11.84M Sep/2025
Alnylam Pharmaceuticals USD 1.49B 376.56M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Arrowhead Research USD 88.71M 41.09M Sep/2025
Astellas Pharma JPY 188.37B 8.51B Mar/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Bayer EUR 5.9B 1.34B Sep/2025
Biogen USD 3.86B 1.1B Sep/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Bristol-Myers Squibb USD 15.73B 3.13B Sep/2025
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Eli Lilly USD 9.79B 6.42B Sep/2025
Exelixis USD 376.3M 211.87M Sep/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Incyte USD 2.93B 508.08M Sep/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Moderna USD 1.13B 147M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
Vertex Pharmaceuticals USD 6.29B 95.8M Sep/2025